Cargando…
A prospective, single-centre, single-arm, open label study of the long term use of a gonadotropin releasing hormone agonist (Triptorelin SR, 11.25 mg) in combination with Tibolone add-back therapy in the management of chronic cyclical pelvic pain
BACKGROUND: Chronic cyclic pelvic pain (CCPP) affects women’s quality of life and pituitary downregulation is often used for symptomatic relief. However, prolonged suppression of ovarian function is associated with menopausal side effects and can lead to osteoporosis. Currently, the use of gonadotro...
Autores principales: | Alshehre, Sallwa M., Duffy, Sheila, Jones, Georgina, Ledger, William L., Metwally, Mostafa |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7155249/ https://www.ncbi.nlm.nih.gov/pubmed/32290838 http://dx.doi.org/10.1186/s12958-020-00586-z |
Ejemplares similares
-
Central Precocious Puberty: Treatment with Triptorelin 11.25 mg
por: Chiocca, Elena, et al.
Publicado: (2012) -
The impact of endometrioma on in vitro fertilisation/intra-cytoplasmic injection IVF/ICSI reproductive outcomes: a systematic review and meta-analysis
por: Alshehre, Sallwa M., et al.
Publicado: (2020) -
Efficacy and safety of diphereline 11.25 mg, microrelin 11.25 mg, and microrelin 3.75 mg in premenopausal patients with breast cancer: a non-inferiority randomized clinical trial
por: Najafi, Safa, et al.
Publicado: (2023) -
The Anticancer Activity Compared Between Triptorelin and a New Gonadotropin Releasing Hormone Analogue
por: Saleh-Abady, Mohammad Mirzaei, et al.
Publicado: (2009) -
Efficacy and Safety Investigation of Kuntai Capsule for the Add-back Therapy of Gonadotropin Releasing Hormone Agonist Administration to Endometriosis Patients: A Randomized, Double-blind, Blank- and Tibolone-controlled Study
por: Chen, Ji-Ming, et al.
Publicado: (2015)